Westport, Connecticut

BioSig Technologies to Present at The LD 500 Virtual Conference

Retrieved on: 
Tuesday, August 25, 2020
Stock market, Westport, Connecticut, Wilton, Connecticut, Microcap stock, LD, Geography of the United States

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

Key Points: 
  • Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.
  • What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.
  • The upcoming "500" in September is LD Micro most ambitious project yet, and the first event that is accessible to everyone.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig Awarded CAGE Code by the Systems for Award Management (SAM)

Retrieved on: 
Monday, August 3, 2020
Contract law, Westport, Connecticut, Government procurement in the United States, Government procurement, Wilton, Connecticut, Commercial and Government Entity code, Contract, Geography of the United States, Law, Articles

The CAGE code is required to do business operations with the federal government.

Key Points: 
  • The CAGE code is required to do business operations with the federal government.
  • The CAGE code also includes the ability to apply and be awarded government contracts, assistance and grant programs.
  • Both current and potential government vendors are required to register in SAM in order to be awarded contracts by the government.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

Ciner Resources to Exit ANSAC on December 31, 2020

Retrieved on: 
Friday, July 31, 2020
Mining, Minerals, Natural Resources, ANSAC, Westport, Connecticut, ANSAC, Ciner Resources Corporation

American Natural Soda Ash Corp. (ANSAC) and Ciner Resources Corporation (Ciner Resources) have reached an agreement for Ciner Resources to exit ANSAC effective December 31, 2020, one year earlier than previously announced.

Key Points: 
  • American Natural Soda Ash Corp. (ANSAC) and Ciner Resources Corporation (Ciner Resources) have reached an agreement for Ciner Resources to exit ANSAC effective December 31, 2020, one year earlier than previously announced.
  • Until the exit date, Ciner Resources will continue to meet its ANSAC membership obligations, which include utilizing ANSAC as Ciner Resources exclusive export sales outlet for U.S.-produced soda ash destined for territories served by ANSAC.
  • Following its exit from ANSAC, Ciner Resources will assume direct responsibility for its export sales and related marketing and logistics requirements that are currently being provided by ANSAC.
  • However, ANSAC has agreed to purchase a limited amount of volume from, and to provide certain logistics services to, Ciner Resources for a limited period after Ciner Resources exit.

BioSig Technologies to Participate in LD Micro’s Zooming with LD

Retrieved on: 
Thursday, July 23, 2020
Westport, Connecticut

Despite the challenging environment, we remained steadfast in securing hospital support for the PURE EP(tm) Systems ongoing and future installations.

Key Points: 
  • Despite the challenging environment, we remained steadfast in securing hospital support for the PURE EP(tm) Systems ongoing and future installations.
  • We are pleased to reconnect with the LD Micro investor community and look forward to reporting on our progress, commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
  • BioSig Technologies, Inc.s (BSGM) subsidiary, ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

David Kelly Returns to Westport Properties, Inc. as Vice President of Development

Retrieved on: 
Wednesday, July 22, 2020
Westport, Connecticut, Cision, Westport Plaza, Westport, Companies

IRVINE, Calif., July 22, 2020 /PRNewswire-PRWeb/ -- Westport Properties, Inc. is excited to announce the return of David Kelly as Vice President of Development.

Key Points: 
  • IRVINE, Calif., July 22, 2020 /PRNewswire-PRWeb/ -- Westport Properties, Inc. is excited to announce the return of David Kelly as Vice President of Development.
  • Kelly previously worked as the Director of Development for five years with the company.
  • "We're thrilled to have David with the Westport Properties family again," said Charles Byerly, President and CEO of Westport Properties and US Storage Centers ("Westport").
  • David Kelly boasts several years of development and construction experience gained at Regency Centers, Snyder Langston, and Standard Pacific Homes.

Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites

Retrieved on: 
Monday, July 13, 2020
Westport, Connecticut

The trial sites are located in Austin, TX, Rochester, MN, Jacksonville, FL, and Scottsdale, AZ.

Key Points: 
  • The trial sites are located in Austin, TX, Rochester, MN, Jacksonville, FL, and Scottsdale, AZ.
  • "Three of our four trial sites where our partners are enrolling patients are in the recognized hot spots of Texas, Arizona, and Florida.
  • We would like to thank our clinical partners for the steady progress with the trial and expect to report the trial data later this summer".
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors

Retrieved on: 
Wednesday, July 1, 2020
Companies, Fiction, Zook, AZN, Westport, Connecticut, AstraZeneca, Zeneca, Wilton, Connecticut

Mr. Zook brings to the Company a wealth of commercialization experience in the life science industry gained primarily through his career at AstraZeneca Plc [LON:AZN].

Key Points: 
  • Mr. Zook brings to the Company a wealth of commercialization experience in the life science industry gained primarily through his career at AstraZeneca Plc [LON:AZN].
  • Along with the CEO, CFO, and Head of R&D, Mr. Zook sat on the Portfolio Investment Board (PIB), which set and approved the overall strategy for Research and Development and allocated resources by therapeutic area.
  • Im pleased to provide my executive and operating expertise to support the Companys goals and objectives, commented Mr. Zook.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering

Retrieved on: 
Monday, June 29, 2020
Westport, Connecticut, Registration statement

The gross proceeds to the Company from this offering were $17.5 million, before deducting placement agent fees and other offering expenses payable by the Company.

Key Points: 
  • The gross proceeds to the Company from this offering were $17.5 million, before deducting placement agent fees and other offering expenses payable by the Company.
  • The Company intends to use the net proceeds from this offering to support commercialization, for working capital and general corporate purposes.
  • The shares of common stock were offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering

Retrieved on: 
Wednesday, June 24, 2020
Westport, Connecticut, Registration statement

The gross proceeds to the Company from this offering are expected to be $17.5 million, before deducting placement agent fees and other offering expenses payable by the Company.

Key Points: 
  • The gross proceeds to the Company from this offering are expected to be $17.5 million, before deducting placement agent fees and other offering expenses payable by the Company.
  • The Company intends to use the net proceeds from this offering to support commercialization and for working capital and general corporate purposes.
  • The shares of common stock are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19

Retrieved on: 
Monday, June 8, 2020
Organic compounds, Viruses, Zoonoses, Medicine, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Westport, Connecticut, Wilton, Connecticut, Remdesivir

The format will be a management presentation updating recent developments followed by a Q&A session with select call attendees.

Key Points: 
  • The format will be a management presentation updating recent developments followed by a Q&A session with select call attendees.
  • The article cites that merimepodib in combination with remdesivir decreases viral production of SARS-CoV-2 to undetectable levels in pre-clinical testing.
  • On May 18, 2020, ViralClear announced the FDAs clearance of its IND to proceed with a proposed Phase II study of merimepodib in COVID-19 patients.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133